Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valbenazine Withdrawal Study in Tardive Dyskinesia
NCT03891862Phase 4Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial of valbenazine in tardive dyskinesia (TD) (3 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Abnormal Involuntary Movement Scale Dyskinesia Total Score at 16 weeks. Started Mar 2019; status: completed.
02
Drugs
valbenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT03891862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891862.